{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T16:00:05Z","timestamp":1765382405381,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ijantimicag.2023.106717","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T11:43:06Z","timestamp":1673437386000},"page":"106717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A single- and multiple-dose study to characterize the pharmacokinetics, safety, and tolerability of ceftolozane\/tazobactam in healthy Chinese participants"],"prefix":"10.1016","volume":"61","author":[{"given":"Na","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jixiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumit","family":"Basu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yudong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francheska","family":"Colon-Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwa-Ping","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqiao","family":"Zang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2023.106717_bib0001","unstructured":"Centers for Disease Control and Prevention (CDC). Antibiotic resistance threats in the United States, https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf; 2019. [accessed 17 February 2022]."},{"key":"10.1016\/j.ijantimicag.2023.106717_bib0002","unstructured":"World Health Organization (WHO). Global action plan on antimicrobial resistance, https:\/\/www.amcra.be\/swfiles\/files\/WHO%20actieplan_90.pdf; 2015. [accessed 17 February 2022]."},{"key":"10.1016\/j.ijantimicag.2023.106717_bib0003","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/S1473-3099(16)30388-7","article-title":"China's national plan to combat antimicrobial resistance","volume":"16","author":"Xiao","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106717_bib0004","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.diagmicrobio.2018.11.021","article-title":"Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015-2017) isolates from hospitalized patients with pneumonia in US medical centers","volume":"94","author":"Carvalhaes","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106717_bib0005","doi-asserted-by":"crossref","first-page":"e01350","DOI":"10.1128\/AAC.01350-17","article-title":"In vitro comparison of ceftolozane-tazobactam to traditional beta-lactams and ceftolozane-tazobactam as an alternative to combination antimicrobial therapy for Pseudomonas aeruginosa","volume":"61","author":"Goodlet","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106717_bib0006","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13756-018-0362-9","article-title":"Carbapenem non-susceptibility of Klebsiella pneumoniae isolates in hospitals from 2011 to 2016, data from the German Antimicrobial Resistance Surveillance (ARS)","volume":"7","author":"Koppe","year":"2018","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.ijantimicag.2023.106717_bib0007","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1086\/499406","article-title":"The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs","volume":"42","author":"Cosgrove","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106717_bib0008","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.3201\/eid2007.121004","article-title":"Deaths attributable to carbapenem-resistant Enterobacteriaceae infections","volume":"20","author":"Falagas","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106717_bib0009","doi-asserted-by":"crossref","first-page":"ofy150","DOI":"10.1093\/ofid\/ofy150","article-title":"Association between carbapenem resistance and mortality among adult, hospitalized patients with serious infections due to Enterobacteriaceae: results of a systematic literature review and meta-analysis","volume":"5","author":"Martin","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106717_bib0010","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2147\/IDR.S236026","article-title":"Contributing factors to the clinical and economic burden of patients with laboratory-confirmed carbapenem-nonsusceptible gram-negative respiratory infections","volume":"13","author":"McCann","year":"2020","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.ijantimicag.2023.106717_bib0011","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2147\/CEOR.S234840","article-title":"Contributing factors to the clinical and economic burden of patients with laboratory-confirmed carbapenem-nonsusceptible gram-negative urinary tract infections","volume":"12","author":"McCann","year":"2020","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.ijantimicag.2023.106717_bib0012","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jhin.2019.06.005","article-title":"Incremental clinical and economic burden of suspected respiratory infections due to multi-drug-resistant Pseudomonas aeruginosa in the United States","volume":"103","author":"Tabak","year":"2019","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.ijantimicag.2023.106717_bib0013","first-page":"345","article-title":"Treatment options for carbapenem-resistant gram-negative infections","volume":"115","author":"Fritzenwanker","year":"2018","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.ijantimicag.2023.106717_bib0014","doi-asserted-by":"crossref","first-page":"e02125","DOI":"10.1128\/AAC.02125-17","article-title":"Activity of ceftolozane-tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates collected from respiratory tract specimens of hospitalized patients in the United States during 2013 to 2015","volume":"62","author":"Castanheira","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106717_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105883","article-title":"Activity of ceftolozane-tazobactam against Gram-negative pathogens isolated from lower respiratory tract infections in the Asia-Pacific region: SMART 2015-2016","volume":"55","author":"Kuo","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106717_bib0016","doi-asserted-by":"crossref","first-page":"e02431","DOI":"10.1128\/AAC.02431-18","article-title":"Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the in vitro activities of ceftazidime-avibactam and ceftolozane-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa","volume":"63","author":"Yin","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106717_bib0017","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane\u2013tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106717_bib0018","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106717_bib0019","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"year":"2020","series-title":"US Prescribing information","key":"10.1016\/j.ijantimicag.2023.106717_bib0020"},{"key":"10.1016\/j.ijantimicag.2023.106717_bib0021","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40262-014-0209-3","article-title":"Interethnic differences in pharmacokinetics of antibacterials","volume":"54","author":"Tsai","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2023.106717_bib0022","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/clpt.2008.141","article-title":"The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies","volume":"84","author":"Yasuda","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2023.106717_bib0023","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/fcp.12227","article-title":"Pharmacokinetics, safety, and tolerability of ceftolozane\/tazobactam in healthy Japanese, Chinese, and white subjects","volume":"30","author":"Aiudi","year":"2016","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2023.106717_bib0024","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jiac.2018.11.005","article-title":"Population pharmacokinetics of tazobactam\/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infection","volume":"25","author":"Kakara","year":"2019","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106717_bib0025","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1093\/jac\/dks246","article-title":"Intrapulmonary penetration of ceftolozane\/tazobactam and piperacillin\/tazobactam in healthy adult subjects","volume":"67","author":"Chandorkar","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106717_bib0026","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1128\/AAC.01753-09","article-title":"Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions","volume":"54","author":"Ge","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106717_bib0027","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1128\/AAC.06349-11","article-title":"Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses","volume":"56","author":"Miller","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106717_bib0028","first-page":"505","article-title":"Pharmacokinetics of YTR830H in healthy human subjects","volume":"1","author":"Cheung","year":"1989","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106717_bib0029","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/jcph.1733","article-title":"Population pharmacokinetic analysis for plasma and epithelial lining fluid ceftolozane\/tazobactam concentrations in patients with ventilated nosocomial pneumonia","volume":"61","author":"Zhang","year":"2021","journal-title":"J Clin Pharmacol"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923000092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923000092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:44:31Z","timestamp":1760377471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857923000092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0924857923000092"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106717","relation":{},"ISSN":["0924-8579"],"issn-type":[{"type":"print","value":"0924-8579"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A single- and multiple-dose study to characterize the pharmacokinetics, safety, and tolerability of ceftolozane\/tazobactam in healthy Chinese participants","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106717","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Merck Sharp & Dohme LLC., a subsidiary Merck & Co., Inc., Rahway, NJ, USA and The Author(s). Published by Elsevier Ltd. on behalf of \tInternational Society of Chemotherapy.","name":"copyright","label":"Copyright"}],"article-number":"106717"}}